Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 4 for:    LY2812176
Previous Study | Return to List | Next Study

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Leap Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01457417
First received: October 18, 2011
Last updated: September 26, 2016
Last verified: September 2016

October 18, 2011
September 26, 2016
January 2012
December 2013   (final data collection date for primary outcome measure)
  • Summary of Total Adverse Events (AE) [ Time Frame: Baseline to study completion (approximately 3 months) ] [ Designated as safety issue: Yes ]
    Total Adverse Events (AE), total treatment emergent adverse events (TEAE), total Serious Adverse Events (SAE), and total dose-limiting toxicity (DLT) for both Parts A and B.
  • Summary of Patients With Adverse Events (AE) [ Time Frame: Baseline to study completion (approximately 3 months) ] [ Designated as safety issue: Yes ]
    Number of patients who had Adverse Events (AE) including treatment related treatment emergent adverse events (TEAE), Common Toxicity Criteria for Adverse Effects (CTCAE), and Serious Adverse Events (SAE) for both Parts A and B. Severity was coded to NCI CTCAE version 4.02. For maximum severity and relationship, patients were counted only once in the most severe or most related category.
  • Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC) [ Time Frame: Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause ] [ Designated as safety issue: No ]
    For Part B only. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (ie, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.
Number of participants with clinically significant effects [ Time Frame: Baseline to study completion (approximately 3 months) ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01457417 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01 [ Time Frame: Cycle 1 Day 1 (first dose, all groups) ] [ Designated as safety issue: No ]
    Area under the DKN-01 serum concentration-time profile curve during the dosing interval (AUC0-tau) after the first and fourth infusion for both Parts A and B. Cycle 1 Day 1 included once per week (QW) dosing groups and every two weeks (Q2W) dosing groups.
  • Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01 [ Time Frame: Cycle 1 Day 22 (Fourth Dose for QW) ] [ Designated as safety issue: No ]
    Area under the DKN-01 serum concentration-time profile curve during the dosing interval (AUC0-tau) after the first and fourth infusion for both Parts A and B. Cycle 1 day 22 included only QW dosing groups.
  • Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01 [ Time Frame: Cycle 1 Day 1 (first dose, all groups) ] [ Designated as safety issue: No ]
    Peak DKN-01 serum concentration (Cmax) after the first and fourth infusion on Cycle 1 Weeks 1 and 4, for both Parts A and B. Cycle 1 Day 1 included once per week (QW) dosing groups and every two weeks (Q2W) dosing groups.
  • Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01 [ Time Frame: Cycle 1 Day 22 (Fourth dose for QW groups) ] [ Designated as safety issue: No ]
    Peak DKN-01 serum concentration (Cmax) after the fourth infusion on Cycle 1 Weeks 1 and 4, for both Parts A and B. Cycle 1 day 22 included only QW dosing groups.
  • Progression Free Survival (PFS) in Patients Who Are Refractory or Intolerant to Standard/Approved Therapies [ Time Frame: Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause ] [ Designated as safety issue: No ]
    For both Parts A and B. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (i.e, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.
  • Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC [ Time Frame: Time from the date of signed informed consent to the date of death from any cause ] [ Designated as safety issue: No ]
    For Part B only. OS was defined as the time from the date of signed informed consent to the date of death from any cause. For patients who were still alive as of the data cut-off date, OS time was censored on the date of the patient's last contact (last contact for patients in post-discontinuation was the last date of contact in long-term follow-up eCRF).
  • Objective Response Rate (ORR) in Oncologic Patients Who Are Refractory or Intolerant to Standard/Approved Therapies [ Time Frame: Part A: Every 2 months; Part B: after 1 month and every two cycles thereafter ] [ Designated as safety issue: No ]
    For both Parts A and B. Objective response rate is defined as the number of patients with overall best response of complete response (CR) or partial response (PR)
  • Objective Response Rate (ORR) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC) [ Time Frame: Part A: Every 2 months; Part B: after 1 month and every two cycles thereafter ] [ Designated as safety issue: No ]
    FAS : For both Parts A and B. Objective response rate is defined as the number of patients with overall best response of complete response (CR) or partial response (PR)
  • Pharmacokinetics: area under the concentration - time curve (AUC) of LY2812176 [ Time Frame: Cycle 1 Day 22 Pre-dose thru Cycle 2 Day 1 Pre-dose ] [ Designated as safety issue: No ]
  • Pharmacokinetic: maximum plasma concentration (Cmax) of LY2812176 [ Time Frame: Cycle 1 Day 22 Pre-dose thru Cycle 2 Day 1 Pre-dose ] [ Designated as safety issue: No ]
  • Pharmacodynamics: Carboxy-terminal Telopeptide of Type I Collagen (ICTP) [ Time Frame: Cycle 1 Day 1 Pre-dose, Cycle 1 Day 15 Pre-dose, Cycle 2 Day 1 Pre-dose, Cycle 2 Day 15 Pre-dose ] [ Designated as safety issue: No ]
  • Pharmacodynamics: Tartrate-resistant Acid Phosphatase Isoform-5b (TRACP-5b) [ Time Frame: Cycle 1 Day 1 Pre-dose, Cycle 1 Day 15 Pre-dose, Cycle 2 Day 1 Pre-dose, Cycle 2 Day 15 Pre-dose ] [ Designated as safety issue: No ]
  • Pharmacodynamics: Bone Alkaline Phosphatase (bALP) [ Time Frame: Cycle 1 Day 1 Pre-dose, Cycle 1 Day 15 Pre-dose, Cycle 2 Day 1 Pre-dose, Cycle 2 Day 15 Pre-dose ] [ Designated as safety issue: No ]
  • Pharmacodynamics: Osteocalcin/Osteoclast (OC) [ Time Frame: Cycle 1 Day 1 Pre-dose, Cycle 1 Day 15 Pre-dose, Cycle 2 Day 1 Pre-dose, Cycle 2 Day 15 Pre-dose ] [ Designated as safety issue: No ]
  • Pharmacodynamics: Procollagen Type-I N-Propeptide (PINP) [ Time Frame: Cycle 1 Day 1 Pre-dose, Cycle 1 Day 15 Pre-dose, Cycle 2 Day 1 Pre-dose, Cycle 2 Day 15 Pre-dose ] [ Designated as safety issue: No ]
  • Measure of tumor response - Response Evaluation Criteria in Solid Tumors (RECIST) and International Myeloma Working Group (IMWG) [ Time Frame: Baseline to study completion (approximately 3 months) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part Phase 1 Multicenter Open-label Study of DKN-01 Given Intravenously. Part A: Dose-Escalation in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: Expansion Cohort in Patients With Relapsed / Refractory Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.
Part A of this trial consists of 4 treatment arms of DKN-01. It is a dose escalation study in patients with multiple myeloma or advanced solid tumors. Patients must be refractory or intolerant to all standard/approved therapy(ies). At each dose level, 3 subjects will be treated. If none of the 3 subjects develop a dose limiting toxicity after a minimum of 4 weeks of treatment, subsequent dose escalation will proceed according to the same schedule. Part B consists of dose confirmation in patients with NSCLC. Patients must be refractory or intolerant to all standard/approved therapy(ies). Approximately 15 patients may be enrolled in Part B.
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Multiple Myeloma
  • Solid Tumors
  • Non-Small Cell Lung Cancer
Drug: DKN-01
DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
Other Name: Formerly LY2812176
  • Experimental: 75 milligram (mg) DKN-01 Part A

    DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.

    PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.

    Intervention: Drug: DKN-01
  • Experimental: 150 mg DKN-01 Part A

    DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.

    PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.

    Intervention: Drug: DKN-01
  • Experimental: 300 mg DKN-01 Part A

    DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.

    PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.

    Intervention: Drug: DKN-01
  • Experimental: 600 mg DKN-01 Part A

    DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.

    PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.

    Intervention: Drug: DKN-01
  • Experimental: 300 mg DKN-01 Part B
    Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
    Intervention: Drug: DKN-01
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Part A: Patients with histological or cytological confirmed multiple myeloma or advanced solid tumors. For multiple myeloma, must have symptomatic myeloma as defined by the International Myeloma Working Group inclusive of measurable serum and/or urine monoclonal protein (M-protein) or for those without elevations they must have measurable increased concentrations of free light chains

Part B: Patients with previously treated, histologically confirmed advanced NSCLC with progressive disease requiring therapy

Parts A and B:

  • Refractory or intolerant to all standard/approved therapy(ies)
  • Patients with solid tumors must have one or more metastatic tumors measurable on computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
  • Radiation for symptomatic lesions outside the central nervous system (CNS) must have been completed at least 2 week prior to study enrollment
  • Treated brain metastases will be allowed, if they are asymptomatic. Patients must be off corticosteroids for at least 2 week prior to study entry
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1
  • Life expectancy of at least 3 months
  • Ambulatory patients greater than or equal to (≥) 30 years of age
  • Females with child bearing potential must have a negative serum pregnancy test within 7 days of study entry
  • Acceptable liver function, renal function, hematologic status
  • Urinalysis - No clinically significant abnormalities
  • Acceptable coagulation status:

    • Prothrombin Time/Partial Thromboplastin Time (PT/PTT) ≤ 1.2 x upper limit of normal (ULN) (unless receiving anticoagulation therapy - eligibility based upon INR)
    • International Normalization Ratio (INR) ≤ 1.6 (unless receiving anticoagulant therapy)

      • Receiving warfarin; INR ≤ 3.0 and no active bleeding
  • For men and women of child-producing potential, the use of effective contraceptive methods during the study and for women 18 months following the last dose of study drug
  • Available for the study duration and willing to follow procedures
  • Serum calcium:

    • Solid tumors only: within normal limits
    • Multiple myeloma: ≤ 11.5 milligrams per deciliter (mg/dL)

Exclusion Criteria:

  • History of osteonecrosis of the hip or evidence of structural bone abnormalities in the proximal femur on magnetic resonance imaging (MRI) scan considered clinically significant or may impact the interpretation of the scan. Degenerative changes of the hip joint are not exclusionary
  • Unable to tolerate the confinement/noise of an MRI scanner or have any contraindication for MRI
  • New York Heart Association Class 3 or 4, cardiac disease, myocardial infarction, unstable arrhythmia, or evidence of ischemia
  • Have Fridericia-corrected QT interval (QTcF) > 470 millisecond (msec) (female) or > 450 (male), or history of congenital long QT syndrome.
  • Active, uncontrolled bacterial, viral, or fungal infections
  • Pregnant or nursing women
  • Radiation therapy, surgery, or chemotherapy, within 1 month prior to study entry
  • Previously treated with an anti-Dickkopf-related protein 1 (DKK-1) therapy
  • Significant allergy to a biological pharmaceutical therapy
  • History of major organ transplant
  • Had an autologous or allogenic bone marrow transplant, current acute leukemia, colon, prostate, breast or small cell lung cancer, osteoblastic lesions, concomitant disease known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism and/or Paget's disease of bone
  • Unwillingness / inability to comply with procedures
  • Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  • Serious nonmalignant disease
  • Receiving other investigational agent or have received other investigational agent within last 30 days or 5 half-lives, whichever is longer
  • Receiving lithium chloride (LiCl)
Both
30 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01457417
P100, DEK-DKK1-P100, LY2812176
No
Not Provided
Not Provided
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
Not Provided
Study Director: Cyndi Sirard, MD Heatlhcare Pharmaceuticals
Leap Therapeutics, Inc.
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP